- Last Updated on Sunday, 20 November 2016 21:12
EU grants 2.1 million euro to Phase Holographic Imaging and Malmö University with partners for joint cancer research
The European Commission has appointed Phase Holographic Imaging, Bundesanstalt für Material-forschung und Prüfung (Germany’s federal technology research institute), Malmö, Umeå, Copenhagen and Turku University to develop improved methods for clinically diagnosing cancer. The €2.1 million grant finances a three-year research project which is coordinated by Malmö University and commercialized by Phase Holographic Imaging (PHI).
Current methods for diagnosing cancer primarily focus on the proteins associated with cancer. However, there is increasing evidence that carbohydrates play an important role in the development and progression of malignant cancer. Current methods use and rely on antibodies created by living organisms. These natural antibodies, however, are not sufficiently specific to accurately detect and image carbohydrates.
“Oncology research and diagnostics are in need of low-cost and robust probes to detect carbohydrates. The project’s goal is to meet this need by combining specific carbohydrate probes – in the form of molecular imprinted polymers or ‘plastic antibodies’ – with holographic microscopy”, said Anette Gjörloff Wingren, Ass. Professor, Malmö University.
“This grant is a milestone for PHI. The recognition by the European Commission shows that the possibili-ties our holographic microscopy technology provides in the battle against cancer is rapidly becoming well known and established in the medical research community”, said CEO Peter Egelberg.
As the commercializing partner of the project, PHI has the right to commercialize the research results to further develop these from prototype to finished product. For more information regarding the research project see Research news at Malmö University (in Swedish).
American Association of Cancer Research highlights article published by PHI collaborators
In the October issue of Molecular Cancer Therapeutics the American Association of Cancer Research (AACR) highlights the novel nanomedicine against ovarian cancer developed by scientists from the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University. PHI maintains the Holographic Imaging Cytometry Program of Excellence at the University since 2014. For more information about the article see dx.doi.org/10.1158/1535-7163.MCT-15-0986.
Ovarian cancer is the deadliest gynecologic malignancy in developed countries. It has a 5-year survival rate of approximately 40% and accounts for 6% of all cancer-related deaths in women in the United States. A combination chemotherapy prolongs the lives of patients. However, the disease recurs in 80% of cases because the tumor cells develop drug resistance.
Using HoloMonitor® M4 the researchers at the University of Chicago and Northeastern University have shown that the new treatment prevents recurring tumor growth by stopping drug resistant cells from dividing.
A HoloMonitor M4 time-lapse sequence of a treated drug resistant ovarian cancer cell which starts to divide but fail.
“In total, our customers and partners have published over 60 scientific publications where the company’s technology has been used. The publications, which are reviewed by independent scientists, show the scientific value of our HoloMonitor technology and thereby its market potential in cancer research and other bioscience applications”, said CEO Peter Egelberg.
A list of the scientific publications can be found here.
Lab of Nobel Prize winner purchases HoloMonitor
The Department of Optical Nanoscopy (Prof. Stefan W. Hell) at the German Cancer Research Center (DKFZ) in Heidelberg recently ordered a motorized HoloMonitor M4. Professor Hell was awarded the Nobel Prize in Chemistry in 2014 for his pioneering work in the field of super-resolution fluorescence microscopy. The customer list price of the ordered unit is 350 000 SEK.
“It is a great honor for us to have the research team of a Nobel Prize winning scientist added to our growing list of customers, selecting our HoloMonitor microscope for their research needs”, said CEO Peter Egelberg.
PHI receives significant order
PHI has received a follow-up order for a minimum of eight motorized HoloMonitor M4 instruments, continuing the strong business performance in the Chinese market. The total customer list price of the ordered instruments amounts to 2.8 MSEK. The instruments will be delivered to PHI’s Chinese distributor during the coming 12 months on a continuous basis. more…
“This order from our Chinese distributor gives us a very nice revenue baseline for the fiscal year 2016/17 that began in May”, said CEO Peter Egelberg.
HoloMonitor technology facilitates cancer research at Florida International University
The first results of the ongoing collaboration between the Department of Environmental and Occupational at Florida International University (FIU) and PHI were presented in April at the annual meeting of the American Association for Cancer Research (AACR).
Cancer stem cells are hypothesized by cancer researches to be the “cancer seed” that causes cancer to spread. The inability to treat metastatic cancer is believed to be a result of that current cancer drugs where primarily developed to kill normal cancer cells, not the cancer stem cells that spread the cancer to other parts of the body. Due to that just a few metastatic cancer cells in the blood stream is sufficient for the cancer to spread, there is today no diagnostic method for detecting metastatic cancer before it is too late in most cases.
The collaboration between FIU and PHI focus on the devastating transformation of breast cells into metastatic cancer stem cells. Spearheaded by Professor Deodutta Roy the researchers at FIU have successfully used PHI’s HoloMonitor® technology to study cancer stem cells ability to move when affected by various cell signals. Additionally, they have shown that these signals also affect the transformation of breast cells into cancer stem cells and their ability to form micro tumors. By interfering with these cell signals the researcher’s hope to develop new and improved cancer treatments. For additional information regarding the collaboration see Fight against cancer fueled by public-private collaborations and FIU's poster at AACR.
“We are particularly encouraged by HoloMonitor’s combined real-time capabilities to study cell motility and 3-dimensional morphology of living normal cells, breast cancer cells and cancer stem cells. We are enthusiastic about continuing the collaboration and anticipate that the HoloMonitor technology will contribute significantly to the understanding of metastatic breast cancer progression and development of novel early noninvasive diagnostic and prognostic biomarkers”, said Prof. Roy.
“It is deeply rewarding to see our HoloMonitor technology contributing to cancer research. The technology’s key strength is quantification of single cell responses to stimuli without affecting the cells, which is fundamental to reliably be able to study living cells”, said Peter Egelberg, CEO.
- “About cancer stem cells” by European Cancer Stem Cell Research Institute
Nature publishes new HoloMonitor article, PHI achieves 50 publications
Researchers at Chinese Academy of Sciences have used HoloMonitor® technology from PHI to investigate cell behavior when Earth’s magnetic field is eliminated. The findings were recently published in Scientific Reports – an online journal published by Nature Publishing Group. According to the researchers, the findings suggest that magnetic field elimination may be used to prevent tumor progression in future clinical applications. The findings also provide clues to which health risks astronauts are exposed to during deep space explorations, where no magnetic field is present.
“This is the second article published by the most prestigious scientific publisher, Nature Publishing Group. The article, together with a recent article by researchers at Linköping University, means that over 50 scientific publications now have been published, in which our HoloMonitor technology plays a significant role”, said CEO Peter Egelberg.
About Chinese Academy of Sciences
Chinese Academy of Sciences (CAS) is China’s national academy for the natural sciences. With its staff of 49 000 researchers CAS has research programs in all areas of natural science. CAS manages the majority of China’s large scale science facilities and China’s scientific space program. Nature Publishing Group ranks CAS as the most productive research organization in the world with over 3 000 scientific articles published in 2014.
PHI raises 4.8 million USD
In a public offering PHI raises 40 million Swedish kronor (4.8 million USD). The raised funds will allow PHI to further address customer needs by developing the company organization and by expanding the HoloMonitor® product line.
PHI is publically traded on AktieTorget and leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the Company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains.
Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.
Cell laboratory at Japanese university orders 3rd HoloMonitor
One of the cell laboratories at Kyushu University in Japan has ordered two HoloMonitor® instruments to complement the instrument previously purchased by the laboratory. The university is one of the seven imperial universities which today form Japan’s prestigious national universities. An additional four HoloMonitor M4.5 instruments have recently been ordered by customers in the UK, Israel, Australia and Singapore. The total retail price of the ordered units amounts to €144 000.
“The follow-up order from Kyushu University once again confirms the scientific value of our HoloMonitor-technology. Furthermore, the order indicates that cell laboratories will require several instruments to accommodate the expanding research needs created by HoloMonitor technology. The laboratory at Kyushu University will become the 9th cell laboratory with several HoloMonitor instruments in operation. Independent market reports estimate the number of cell laboratories in the world to approximately 120 000”, said CEO Peter Egelberg.
Nature publish HoloMonitor research
Researchers at Lund University have used HoloMonitor® technology from Phase Holographic Imaging to investigate the behavior of cells when cultivated on nanowires. The findings were recently published in Scientific Reports – an online journal published by Nature Publishing Group.
Using HoloMonitor the researchers investigated the effects of nanowire density on cell movement, division and morphology. The results provide guidelines to minimize cellular stress on nanowire arrays. Additionally, the findings show that cell behavior can be controlled by adjusting nanowire density, which may have applications in drug development.
“Nature Publishing Group is the most prestigious scientific publisher. Nature’s publication is a milestone and the highlight of the publications in 2015. 14 publications were published in 2015, which is an increase by 100 % compared to 2014. In total well over 40 scientific publications have now been published, in which our HoloMonitor technology plays a significant role”, said CEO Peter Egelberg.